fashion -WSS

fashion

author：knowledge 2025-10-01 00:47:40 - browse：9

Robert F. Kennedy Jr. said Tuesday that he will head up a panel on vaccine safety for Donald Trump.

The president-elect’s transition team spokeswoman later walked that back, saying that he is “exploring the possibility” of forming a panel on autism, but “no decisions have been made.”

Let’s hope Trump drops any idea of a vaccine panel headed by Kennedy. For more than a decade, Kennedy has promoted anti-vaccine propaganda completely unconnected to reality. If Kennedy’s panel leads to even a small decline in vaccine rates across the country, it will result in the waste of untold amounts of money and, in all likelihood, the preventable deaths of infants too young to be vaccinated.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： The real point of Kenneth Smith’s execution by nitrogen gas

hotspot

WSS

Questions loom on AstraZeneca cancer drug as safety concerns ebb

A $475,000 price tag for a new cancer drug: crazy or meh?

FDA clears Verve to begin U.S. study of gene

Cybersecurity threat forces Lurie Children's to take systems offline

Do digital therapeutics have a future in medicine?

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

entertainment

fashion

Wikipedia

FDA approval of Sarepta Duchenne genetic therapy gives me hope

STAT Summit: Meghan O’Rourke on making chronic illness visible

In age of alternative facts, a scholarly course on calling out crap

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

Anesthesiologist group: stop taking Ozempic before surgery

Medicare drug price negotiation’s day in court

The high cost of giving birth even with insurance

Apple Vision Pro: A first look at health apps on the new VR headset

Moonlake's readout produced a cash windfall. Risks remain

Roche drug slashes death risk in early

Wikipedia

Medicare drug price negotiation’s day in court

Health tech investors get more selective as pandemic boom fades

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

Vertigo drug brings hope for rare neuron disorder, Niemann

STAT Summit: Ending the crisis of Black deaths in the U.S.

leisure time

hotspot

hotspot

focus